Business Wire

Garmin® announces passing of Co-founder and Chairman Emeritus Gary Burrell

13.6.2019 19:21:00 EEST | Business Wire | Press release

Share

Garmin International, Inc., a unit of Garmin Ltd. (NASDAQ:GRMN), today announced that Gary Burrell, aviation pioneer and co-founder of Garmin Ltd., passed away on June 12, 2019, at the age of 81. Mr. Burrell retired in 2002 and continued to serve as Garmin’s co-Chairman until 2004 when he was named Chairman Emeritus.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190613005579/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Garmin® announces passing of Co-founder and Chairman Emeritus Gary Burrell. Innovator, entrepreneur and servant leader will be remembered for his legacy of growing Garmin from a start-up company to a global leader in GPS technology. (Photo: Business Wire)

Mr. Burrell co-founded Garmin with Dr. Min Kao in 1989 with the vision of creating products powered by an emerging technology known as the Global Positioning System, or GPS. Thirty years later, Garmin has grown from a handful of engineers into a global location and communication product powerhouse with more than 13,000 associates in 60 offices around the world. Of his many accomplishments, Gary was most proud of the jobs he helped create.

"Gary Burrell has been my friend, mentor and partner for more than 30 years," Kao said. "His vision, values, engineering skills and commitment to serving our customers have been the foundation for the growth of our company. It has been both a great privilege and a blessing to have known this amazing man and I know his legacy will live on."

In a career spanning 50 years, Burrell motivated and mentored thousands of employees. Among them was Garmin President and CEO Cliff Pemble, one of Burrell’s first hires.

“While Gary will be remembered by many as one of the great entrepreneurs of our age, I will remember the unusual way in which he led our company, something he called servant leadership,” Pemble said. “Whether it was about creating the best product or his behavior as a leader, Gary always considered the impact to others before himself. His example not only inspired my contribution to Garmin, it also positively influenced me as a husband and father. I am forever grateful for the rich and enduring legacy of Gary Burrell.”

Prior to launching Garmin in 1989, Burrell held leadership positions at marine and aviation electronics companies including Lowrance Electronics, King Radio Corporation and AlliedSignal. He is widely regarded as one of the leading innovators of integrated avionics, having designed and developed the first successful NAV/COMM for the general aviation market.

At Garmin, Gary expanded his vision for integration with the GNS 430/530 product family, which combines GPS technology with traditional aviation navigation and communication systems and a color moving map. Gary went on to conceive the G1000 cockpit system which today is operating in thousands of aircraft around the world from small piston powered airplanes through mid-sized business jets. Burrell earned his bachelor’s in electrical engineering at Wichita State University and his master’s from Rensselaer Polytechnic Institute.

For decades, Garmin has pioneered new GPS navigation and wireless devices and applications that are designed for people who live an active lifestyle. Garmin serves five primary markets, including automotive, aviation, fitness, marine, and outdoor recreation. For more information, visit Garmin's virtual pressroom at garmin.com/newsroom, contact the Media Relations department at 913-397-8200, or follow us at facebook.com/garmin, twitter.com/garmin, instagram.com/garmin or youtube.com/garmin.

About Garmin International Inc.

Garmin International Inc. is a subsidiary of Garmin Ltd. (Nasdaq: GRMN). Garmin Ltd. is incorporated in Switzerland, and its principal subsidiaries are located in the United States, Taiwan and the United Kingdom. Garmin is a registered trademark of Garmin Ltd. or its subsidiaries.

All other brands, product names, company names, trademarks and service marks are the properties of their respective owners. All rights reserved.

Notice on Forward-Looking Statements:

This release includes forward-looking statements regarding Garmin Ltd. and its business. Such statements are based on management’s current expectations. The forward-looking events and circumstances discussed in this release may not occur and actual results could differ materially as a result of known and unknown risk factors and uncertainties affecting Garmin, including, but not limited to, the risk factors listed in the Annual Report on Form 10-K for the year ended December 29, 2018, filed by Garmin with the Securities and Exchange Commission (Commission file number 0-31983). A copy of such Form 10-K is available at http://www.garmin.com/aboutGarmin/invRelations/finReports.html. No forward-looking statement can be guaranteed. Forward-looking statements speak only as of the date on which they are made and Garmin undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Krista Klaus
Garmin International, Inc.
Phone | 913-397-8200
E-Mail | media.relations@garmin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye